# Eli Lilly and Co.: Insulin Lispro Injection to be discontinued

**Score:** 60/100

| Field | Value |
|---|---|
| Manufacturer | Eli Lilly and Co. |
| Drug | Insulin Lispro Injection |
| Dosage form | Injection |
| Therapeutic category | Endocrinology/Metabolism |
| Status | To Be Discontinued |
| Stage | Manufacturer discontinuation |
| Presentations affected | 1 |
| Package NDCs | 0002-7752-05 |
| Manufacturer supply note | A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance. |
| Discontinued date | 2026-09-01 |
| First posted | 2026-09-01 |
| Updated | 2026-09-01 |

## Why this score
- The manufacturer is leaving the market.
- Sterile injectable: hospital and 503B demand.

Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) (https://dps.fda.gov/drugshortages). Last refreshed: 2026-11-04T06:10:12.565Z.
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.